Publication Year

Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, … Kelsh MA, et al. 2016. Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(1):8–26; doi: 10.1093/annhyg/mev060.

Hummel HD, Topp MS, Chang ET, Chia VM, Kelsh MA, Doemland ML, et al. 2016. Adverse events in adults with relapsed or refractory acute lymphoblastic leukemia (ALL): A literature review of recent clinical trials. J Leuk 4(1):208; doi: 10.4172/2329-6917.1000208.

Fryzek J, Alexander DD, Summers N, Fraysse J, Reichert H, Townes L, Vanderpuye-Orgle J. 2016. Indirect treatment comparison of cabazitaxel for patients with metastatic castration-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. Value in Health 3:A139-A140.

Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, … Kelsh M, et al. 2016. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101(12):1524–1533; doi: 10.3324/haematol.2016.144311. PMID: 27587380.

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473.

Alexander DD, Bylsma LC, Elkayam L, Nguyen DL. 2016. Nutritional and health benefits of semi-elemental diets: A comprehensive summary of the literature. World J Gastrointest Pharmacol Ther 7(2):306-319; doi: 10.4292/wjgpt.v7.i2.306.

Cetin K, Callaghan F, Fryzek J, Bylsma L, Bezold C, Mehta B. Safety and efficacy/effectiveness of second-line treatments in patients with Immune Thrombocytopenia: A systematic review of the literature. Presented at the 21st Congress of the European Hematology Association, Copenhagen, Denmark, June 2016.

De Flora S, Camoirano A, Micale RT, La Maestra S, Savarino V, Zentilin P, Marabotto E, Suh M, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  I. Chemical reduction and mitigation of mutagenicity. Toxicol Appl Pharmacol 306(Sept 1):113-119; doi: 10.1016/j.taap.2016.07.004. PMID: 27404458.

Kirman CR, Suh M, Hays SM, Gürleyük H, Gerads R, De Flora S, Parker W, Lin S, Haws LC, Harris MA, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid. II. Ex vivo gastric reduction modeling. Toxicol Appl Pharmacol 306(Sep 1):120-133; doi: 10.1016/j.taap.2016.07.002. PMID: 27396814.

Kelsh MA. Evaluating biosimilars in observational data: Some methodological considerations. Presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland, August 25–28, 2016.